Positive News SentimentPositive NewsNASDAQ:XENE Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free XENE Stock Alerts $40.52 +0.42 (+1.05%) (As of 03:08 PM ET) Add Compare Share Share Today's Range$39.80▼$40.8750-Day Range$39.50▼$49.6352-Week Range$27.99▼$50.99Volume183,883 shsAverage Volume396,211 shsMarket Capitalization$3.06 billionP/E RatioN/ADividend YieldN/APrice Target$59.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Xenon Pharmaceuticals alerts: Email Address Xenon Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside46.5% Upside$59.44 Price TargetShort InterestHealthy3.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.61Based on 2 Articles This WeekInsider TradingSelling Shares$931,940 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.04) to ($3.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.65 out of 5 starsMedical Sector438th out of 908 stocksPharmaceutical Preparations Industry195th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXenon Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.47% of the outstanding shares of Xenon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently decreased by 5.07%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XENE. Previous Next 2.6 News and Social Media Coverage News SentimentXenon Pharmaceuticals has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Xenon Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for XENE on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $931,940.00 in company stock.Percentage Held by InsidersOnly 5.43% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($3.04) to ($3.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -14.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -14.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About Xenon Pharmaceuticals Stock (NASDAQ:XENE)Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.Read More XENE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XENE Stock News HeadlinesApril 18, 2024 | americanbankingnews.comInvestors Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)April 16, 2024 | globenewswire.comXenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual MeetingApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? April 16, 2024 | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by AnalystsApril 10, 2024 | investing.comXenon Pharmaceuticals Inc (XENE)April 10, 2024 | globenewswire.comXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 4, 2024 | globenewswire.comXenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 21, 2024 | money.usnews.comXenon Pharmaceuticals IncApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? March 19, 2024 | finance.yahoo.comXenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth PlansMarch 16, 2024 | finance.yahoo.comXENE Apr 2024 47.500 putMarch 12, 2024 | globenewswire.comXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS DaysMarch 9, 2024 | finance.yahoo.comInsider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...March 5, 2024 | globenewswire.comXenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024March 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline ProgressMarch 2, 2024 | seekingalpha.comXenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finanznachrichten.deXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 1, 2024 | markets.businessinsider.comBuy Rating Justified by Xenon Pharmaceuticals’ Advanced Epilepsy Program and Growth Prospects in NeuroscienceFebruary 29, 2024 | finance.yahoo.comXenon Pharmaceuticals Inc (XENE) Reports Full Year and Q4 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comXenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 22, 2024 | globenewswire.comXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateFebruary 21, 2024 | investorplace.com3 Biotech Stocks That Could Be Multibaggers in the Making: February EditionFebruary 8, 2024 | seekingalpha.comXenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'February 7, 2024 | finance.yahoo.comIs Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Trading At A 39% Discount?January 23, 2024 | finance.yahoo.comHere's Why You Should Add Xenon (XENE) to Your Portfolio NowJanuary 19, 2024 | finance.yahoo.comWall Street Analysts Think Xenon Pharmaceuticals (XENE) Could Surge 25.76%: Read This Before Placing a BetSee More Headlines Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/26/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XENE CUSIPN/A CIK1582313 Webwww.xenon-pharma.com Phone(604) 484-3300Fax604-484-3450Employees251Year FoundedN/APrice Target and Rating Average Stock Price Target$59.44 High Stock Price Target$65.00 Low Stock Price Target$51.00 Potential Upside/Downside+47.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-182,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-25.18% Return on Assets-23.99% Debt Debt-to-Equity RatioN/A Current Ratio23.65 Quick Ratio23.65 Sales & Book Value Annual Sales$9.43 million Price / Sales323.48 Cash FlowN/A Price / Cash FlowN/A Book Value$14.18 per share Price / Book2.85Miscellaneous Outstanding Shares75,430,000Free Float71,336,000Market Cap$3.05 billion OptionableOptionable Beta1.15 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Ian C. Mortimer C.M.A. (Age 48)CPA, M.B.A., President, CEO & Director Comp: $973.76kMs. Sherry Aulin (Age 40)Chief Financial Officer Comp: $3.03MMs. Andrea DiFabio J.D. (Age 56)Chief Legal Officer & Corporate Secretary Comp: $200.51kDr. Christopher E. Von Seggern M.B.A. (Age 45)M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer Comp: $618.07kDr. Christopher John Kenney M.D. (Age 53)Chief Medical Officer Comp: $684.22kMs. Shelley McCloskey B.A. (Age 64)Executive Vice President of Human Resources Dr. Robin P. Sherrington Ph.D. (Age 63)Executive Vice President of Strategy & Innovation Comp: $351.67kDr. James R. Empfield Ph.D. (Age 63)Executive Vice President of Drug Discovery Comp: $323.43kMs. Sheila M. Grant M.B.A.M.Sc., MBA, Executive Vice President of R&D OperationsMore ExecutivesKey CompetitorsBausch Health CompaniesNYSE:BHCCrinetics PharmaceuticalsNASDAQ:CRNXAmicus TherapeuticsNASDAQ:FOLDHUTCHMEDNASDAQ:HCMArrowhead PharmaceuticalsNASDAQ:ARWRView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 86,875 shares on 4/24/2024Ownership: 0.247%17 Capital Partners LLCBought 2,840 shares on 4/11/2024Ownership: 0.004%PNC Financial Services Group Inc.Bought 1,980 shares on 3/22/2024Ownership: 0.003%Sherrington RobinSold 7,137 sharesTotal: $330,300.36 ($46.28/share)Steven GannonSold 13,000 sharesTotal: $601,640.00 ($46.28/share)View All Insider TransactionsView All Institutional Transactions XENE Stock Analysis - Frequently Asked Questions Should I buy or sell Xenon Pharmaceuticals stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XENE shares. View XENE analyst ratings or view top-rated stocks. What is Xenon Pharmaceuticals' stock price target for 2024? 9 brokerages have issued 1-year price objectives for Xenon Pharmaceuticals' shares. Their XENE share price targets range from $51.00 to $65.00. On average, they expect the company's stock price to reach $59.44 in the next twelve months. This suggests a possible upside of 46.5% from the stock's current price. View analysts price targets for XENE or view top-rated stocks among Wall Street analysts. How have XENE shares performed in 2024? Xenon Pharmaceuticals' stock was trading at $46.06 on January 1st, 2024. Since then, XENE stock has decreased by 11.9% and is now trading at $40.59. View the best growth stocks for 2024 here. When is Xenon Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our XENE earnings forecast. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.12. Xenon Pharmaceuticals's revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.57) EPS. What ETFs hold Xenon Pharmaceuticals' stock? ETFs with the largest weight of Xenon Pharmaceuticals (NASDAQ:XENE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Fidelity Disruptive Medicine ETF (FMED), BlackRock Future Health ETF (BMED), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), BNY Mellon Innovators ETF (BKIV) and Goldman Sachs Future Health Care Equity ETF (GDOC). What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI). Who are Xenon Pharmaceuticals' major shareholders? Xenon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.25%) and 17 Capital Partners LLC (0.00%). Insiders that own company stock include Christopher John Kenney, Dawn Svoronos, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Seggern Christopher Von, Sherrington Robin, Simon N Pimstone and Steven Gannon. View institutional ownership trends. How do I buy shares of Xenon Pharmaceuticals? Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XENE) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.